Comprehensive treatment of metastatic hormone sensitive prostate cancer: a case report and literature review
10.3760/cma.j.cn112330-20210408-00014
- VernacularTitle:转移性激素敏感性前列腺癌综合治疗一例报告并文献复习
- Author:
Guowen LIN
1
;
Bo DAI
;
Dingwei YE
;
Yao ZHU
;
Xiaojian QIN
;
Hongkai WANG
Author Information
1. 复旦大学附属肿瘤医院泌尿外科 复旦大学上海医学院肿瘤学系，上海 200232
- Keywords:
Prostate cancer;
Metastasis;
Hormone sensitive;
Abiraterone;
Palliative transurethral resection of the prostate
- From:
Chinese Journal of Urology
2021;42(Z1):54-58
- CountryChina
- Language:Chinese
-
Abstract:
Retrospectively analyze the clinicopathological data of a patient with metastatic hormone sensitive prostate cancer, and review relevant literature. The patient was male, 68 years old. Complaints of dysuria and urgency for half a year. Blood PSA>100 ng/ml, magnetic resonance showed that the prostate was occupying space, the boundary with the seminal vesicle gland was not clear, and the pelvic cavity had multiple bone lesions. Bone scan revealed multiple bone metastases. The prostate biopsy showed adenocarcinoma, Gleason score 5+ 5. The clinical stage was T 3N 0M 1b.A palliative transurethral resection of the prostate was performed due to urination obstruction, and endocrine therapy with medical castration combined with abiraterone and prednisone. PSA was continuously controlled at <0.006 ng/ml. After half a year of treatment, the prostate-specific membrane antigen single-photon emission computerized tomography and magnetic resonance examination revealed sternal and parasternal soft tissue lesions. Local radiotherapy and continuous endocrine therapy were given. The disease was under long-term control.There are various treatment options for metastatic hormone sensitive prostate cancer. Medical castration treatment combined with abiraterone and prednisone can effectively control the disease with mild adverse reactions. Palliative transurethral resection of the prostate can improve the symptoms of urinary obstruction and may also improve the prognosis of patients.
